title: Next generation TAVI with the Lotus Valve System: a repositionable and fully retrievable transcatheter aortic valve prosthesis.
abstract: Transcatheter aortic valve implantation (TAVI) is the new standard of care for selected patients with severe symptomatic aortic stenosis who are at high risk for surgical aortic valve replacement (AVR), or are inoperable. Multicentre randomised controlled trials have demonstrated equivalent or superior clinical outcomes for TAVI compared to AVR in carefully selected patient cohorts. A number of important limitations were observed with early generation TAVI valves and their delivery systems, and rapid evolution of the technology continues. The Lotus Valve System aims to address a number of these limitations - it is repositionable and retrievable, and has an adaptive seal to prevent paravalvular aortic regurgitation. Early clinical outcomes for the Lotus Valve System have recently been published with promising results in terms of paravalvular regurgitation and repositionability.
authors.affiliation: Heart and Lung Institute, The Prince Charles Hospital, Brisbane, Australia - darren.walters@health.qld.gov.au.
authors.forename: D
authors.initials: D
authors.lastname: Murdoch
authors.forename: E
authors.initials: E
authors.lastname: Shaw
authors.forename: O C
authors.initials: OC
authors.lastname: Raffel
authors.forename: D L
authors.initials: DL
authors.lastname: Walters
mesh_terms: D001022:Aortic Valve Insufficiency / Q000517:prevention & control*; D001024:Aortic Valve Stenosis / Q000503:physiopathology / Q000601:surgery*; D006350:Heart Valve Prosthesis; D019918:Heart Valve Prosthesis Implantation / Q000379:methods; D006801:Humans; D018579:Patient Selection; D011474:Prosthesis Design; D016032:Randomized Controlled Trials as Topic; D065467:Transcatheter Aortic Valve Replacement / Q000295:instrumentation / Q000379:methods*